{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:48:45Z","timestamp":1780602525803,"version":"3.54.1"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the effects of abituzumab in systemic sclerosis\u2013associated interstitial lung disease (SSc-ILD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>STRATUS was a phase II, double-blind, parallel-group, multicenter trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02745145\">NCT02745145<\/jats:ext-link>). Adults (\u2264 75 yrs) with SSc-ILD on stable mycophenolate were randomized (2:2:1) to receive intravenous abituzumab 1500 mg, abituzumab 500 mg, or placebo every 4 weeks for 104 weeks. The primary endpoint was the annual rate of change in absolute forced vital capacity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>STRATUS was terminated prematurely due to slow enrollment (n = 75 screened, n = 24 randomized), precluding robust analysis of efficacy. Abituzumab was well tolerated; no new safety signals were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Further investigation of abituzumab for treatment of SSc-ILD is required.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.191365","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T16:39:35Z","timestamp":1601570375000},"page":"1295-1298","source":"Crossref","is-referenced-by-count":27,"title":["STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis\u2013associated Interstitial Lung Disease"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-4872","authenticated-orcid":false,"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Seibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Vazquez-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fleuranceau-Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Damian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"2022062114102974000_48.8.1295.1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5114\/reum.2018.77977","article-title":"Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management","volume":"56","author":"Chowaniec","year":"2018","journal-title":"Reumatologia"},{"key":"2022062114102974000_48.8.1295.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3636-7"},{"key":"2022062114102974000_48.8.1295.3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rdc.2015.04.006","article-title":"Management of systemic-sclerosis-associated interstitial lung disease","volume":"41","author":"Silver","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2022062114102974000_48.8.1295.4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10067-013-2289-0","article-title":"Mortality in systemic sclerosis\u2013a single centre study from the UK","volume":"32","author":"Strickland","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2022062114102974000_48.8.1295.5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Khanna","year":"2019","journal-title":"Rheumatology"},{"key":"2022062114102974000_48.8.1295.6","doi-asserted-by":"crossref","first-page":"208219","DOI":"10.1155\/2011\/208219","article-title":"Blocking TGF\u0392 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease","volume":"2011","author":"Katsumoto","year":"2011","journal-title":"Int J Rheumatol"},{"key":"2022062114102974000_48.8.1295.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00210414"},{"key":"2022062114102974000_48.8.1295.8","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201201-003AW"},{"key":"2022062114102974000_48.8.1295.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu474"},{"key":"2022062114102974000_48.8.1295.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2512"},{"key":"2022062114102974000_48.8.1295.11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2022062114102974000_48.8.1295.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"2022062114102974000_48.8.1295.13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2022062114102974000_48.8.1295.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2022062114102974000_48.8.1295.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.191365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:18:45Z","timestamp":1655846325000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.191365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.3899\/jrheum.191365"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.191365","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}